Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01HL136682-01 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
| University of Michigan | OTHER |
| National Jewish Health | OTHER |
| University of Minnesota |
Not provided
Not provided
Not provided
Not provided
A prospective multi-center study to define the sensitivity and specificity of CAPTURE for identifying previously undiagnosed patients with clinically significant COPD in a broad range of primary care settings.
The CAPTURE tool consists of a 5-item self-administered questionnaire and selected use of peak expiratory flow (PEF) measurement, designed to identify clinically significant COPD.
For Aim 1 approximately 5,000 patients will be recruited across 100 participating primary care clinics. Eligible participants will undergo a baseline visit during which the CAPTURE tool and PEF will be obtained, as well as spirometry and other participant characteristics.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants without a diagnosis of COPD | Men and women aged 45 to 80, who have not been diagnosed with Chronic Obstructive Pulmonary Disease (COPD) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CAPTURE Tool | Other | CAPTURE Tool: a self administered 5-item questionnaire with peak expiratory flow measurements |
|
| Measure | Description | Time Frame |
|---|---|---|
| Sensitivity and specificity of CAPTURE to identify previously undiagnosed patients with clinically significant COPD at baseline | Sensitivity and specificity of CAPTURE to identify previously undiagnosed patients with clinically significant COPD at baseline. Clinically significant COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC < 0.7, plus one of the following: FEV1 < 60% predicted, or ≥ 1 exacerbation-like event within the past 12 months. If a participant is unable to complete a post-bronchodilator spirometry (refusal, technical error on the part of coordinator, etc.), and the pre-bronchodilator FEV1/FVC is less than 0.65, the participant will be considered to have COPD for the purpose of follow-up in this study. | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Sensitivity and specificity of CAPTURE to identify previously undiagnosed patients with clinically significant COPD across sex, ethnic groups, urban vs rural location, and educational status. | Sensitivity and specificity of CAPTURE to identify previously undiagnosed patients with COPD across sex, ethnic groups, urban vs rural location, and educational status. | Baseline |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Previous clinician provided diagnosis of COPD
Treated respiratory infection (with antibiotics and/or systemic steroids) in the past 30 days of baseline
Participants unable to perform spirometry due to any of the following conditions within the past 30 days of baseline
Not provided
Not provided
Adult men and women recruited from a broad range of primary care settings across the United States.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Fernando J Martinez, MD, MS | Weill Medical College of Cornell University | Principal Investigator |
| MeiLan Han | University of Michigan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| LANet | Los Angeles | California | 90802 | United States | ||
| High Plains Research Network |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39715575 | Derived | Martinez FJ, Yawn BP, Angulo D, Lopez C, Murray S, Mannino D, Anderson S, Dolor R, Elder N, Joo M, Khan I, Knox LM, Meldrum C, Peters E, Spino C, Tapp H, Thomashow B, Zittleman L, Brown R, Make B, Han MK; CAPTURE Study Group. Impact of the CAPTURE Chronic Obstructive Pulmonary Disease Screening Tool in U.S. Primary Care: A Cluster-Randomized Trial. Am J Respir Crit Care Med. 2025 May;211(5):789-802. doi: 10.1164/rccm.202405-0921OC. |
Not provided
Not provided
Not provided
| OTHER |
| Duke University | OTHER |
| Wake Forest University Health Sciences | OTHER |
| Oregon Health and Science University | OTHER |
| High Plains Research Network | NETWORK |
| L.A. Net Community Health Resource Network | OTHER |
| COPD Foundation | OTHER |
| University of Kentucky | OTHER |
Not provided
Not provided
Not provided
| Positive and negative predictive values (PPV and NPV) in different practice settings | Positive and negative predictive values in different practice settings | Baseline |
| Areas under the receiving operator characteristic curve (AUC) for various cutpoints of CAPTURE and PEF (Peak expiratory flow) measurements to determine the best cutpoint for clinically significant COPD screen | AUC for various cutpoints of CAPTURE and PEF measurements to determine the best cutpoint for clinically significant COPD screen. | Baseline |
| AUC to identify the combination of patient/site characteristics which best discriminates those with clinically significant COPD | AUC to identify the combination of patient/site characteristics which best discriminates those with clinically significant COPD | Baseline |
| Sensitivity and specificity of CAPTURE to identify previously undiagnosed patients with spirometrically defined COPD at baseline | Sensitivity and specificity of CAPTURE to identify previously undiagnosed patients with Spirometrically defined COPD at baseline. Spirometrically defined COPD is defined as post-bronchodilator FEV1/FVC < 0.70. | Baseline |
| Sensitivity and specificity of CAPTURE to identify previously undiagnosed patients with spirometrically defined COPD across sex, ethnic groups, urban vs rural location, and educational status. | Sensitivity and specificity of CAPTURE to identify previously undiagnosed patients with spirometrically defined COPD across sex, ethnic groups, urban vs rural location, and educational status. Spirometrically defined COPD is defined as post-bronchodilator FEV1/FVC < 0.70 | Baseline |
| Areas under the receiving operator characteristic curve (AUC) for various cutpoints of CAPTURE and PEF (Peak expiratory flow) measurements to determine the best cutpoint for spirometrically defined COPD screen | AUC for various cutpoints of CAPTURE and PEF measurements to determine the best cutpoint for spirometrically defined COPD (FEV1/FVC < 0.70) screen. | Baseline |
| AUC to identify the combination of patient/site characteristics which best discriminates those with spirometrically defined COPD | AUC to identify the combination of patient/site characteristics which best discriminates those with spirometrically defined COPD (FEV1/FVC < 0.70). | Baseline |
| Sensitivity and specificity of CAPTURE to identify previously undiagnosed patients with mild COPD at baseline | Sensitivity and specificity of CAPTURE to identify previously undiagnosed patients with mild COPD at baseline. Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC < 0.7, plus both of the following: FEV1 > 60% predicted and no prior history of COPD exacerbation. | Baseline |
| Sensitivity and specificity of CAPTURE to identify previously undiagnosed patients with mild COPD across sex, ethnic groups, urban vs rural location, and educational status. | Sensitivity and specificity of CAPTURE to identify previously undiagnosed patients with mild COPD across sex, ethnic groups, urban vs rural location, and educational status. Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC < 0.7, plus both of the following: FEV1 > 60% predicted and no prior history of COPD exacerbation. | Baseline |
| Areas under the receiving operator characteristic curve (AUC) for various cutpoints of CAPTURE and PEF (Peak expiratory flow) measurements to determine the best cutpoint for mild COPD screen | AUC for various cutpoints of CAPTURE and PEF measurements to determine the best cutpoint for mild COPD screen. Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC < 0.7, plus both of the following: FEV1 > 60% predicted and no prior history of COPD exacerbation. | Baseline |
| AUC to identify the combination of patient/site characteristics which best discriminates those with mild COPD | AUC to identify the combination of patient/site characteristics which best discriminates those with mild COPD. Mild COPD is defined as participants with abnormal spirometry, defined as post-bronchodilator FEV1/FVC < 0.7, plus both of the following: FEV1 > 60% predicted and no prior history of COPD exacerbation. | Baseline |
| Aurora |
| Colorado |
| 80054 |
| United States |
| COPD Foundation | Miami | Florida | 33134 | United States |
| Cook County Health | Chicago | Illinois | 60612 | United States |
| University of Illinois at Chicago | Chicago | Illinois | 60612 | United States |
| Atrium Healthcare | Charlotte | North Carolina | 28207 | United States |
| Duke University | Durham | North Carolina | 27701 | United States |
| Oregon Rural Practice-based Research Network (ORPRN) | Portland | Oregon | 97239 | United States |
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided